Skip to main content

Global Companion Diagnostics Market Is Projected to Reach $7,536.7 Million by 2030

 

As depicted, the genome sequencing cost is decreasing while the production (TB) is increasing. It is expected that the cost of genome sequencing would ultimately drop to as low as $100 by 2025. As a result, it is highly possible that the use of genome sequencing will become more widely adopted and integrated into regular clinical practice, thereby bolstering the scope of companion diagnostic usage across the healthcare continuum for treatment preferences.

As per BIS Research analysis, the global companion diagnostics market is projected to reach $7,536.7 million by 2030 from $1,764.7 million in 2019, at a CAGR of 12.45% during the forecast period of 2020-2030. This growth has been primarily attributed to the major drivers in this market, which comprise the growing incidence of cancer within the global population that has intensified the demand for better treatment assurance for all cancer types. Additionally, the growing demand for personalized medicine and the regulatory mandate for the co-development of drugs and diagnostics are driving the growth of the global CDx market. The market is expected to grow at a significant growth rate due to the opportunities that lie within its domain, which include the development of multiple-biomarker based CDx, powered by NGS technology, commercialization of CDx for non-oncology disease areas, and exploitation of advance data science technology in the field of companion diagnostics. However, there are significant challenges which are restraining the market growth. These challenges include an uncertain reimbursement scenario, companion diagnostics leakage in oncology and weak synchronization between therapeutics and diagnostics in marketing and distribution channels.

The BIS Research report on the global companion diagnostics market segments the market on the basis of technology (in-situ hybridization, immunohistochemistry, polymerase chain reaction, and next-generation sequencing), application area (lung cancer, breast cancer, colorectal cancer, leukemia, melanoma, stomach cancer, and others), and region (North America, Europe, Asia-Pacific, and Rest-of-the-World).

Labels:

Comments

Post a Comment

Popular posts from this blog

Understanding How the Human Centric Lighting Market is Segmented

Lighting plays a significant role in the lives of people, it has the potential to bring about positive changes in people’s behaviour. In the year 1989, a research was carried out and it proved that natural daylight can trigger the production of melatonin and serotonin, two of the most important hormones in the human body. These two hormones are responsible for inducing peaceful sleep and happiness in people. This led to the research and development in the field of human centric lighting (HCL). According to a report published by the BIS Research , the HCL market is expected to grow at a CAGR of 37.2% and 35.2% both in terms of volume and value during the forecast period (2018 – 2024). The HCL is segmented by the component, end-user and by region. Request the Sample: Human Centric Lighting Market The human centric lighting market can be further segmented by component, type, end-users, and region. The components or the controls are further segmented as microprocessors & microco...
Post a Comment
Read more

Liquid Biopsy, North America, and Lung Cancer Occupying a Major Share in the Market

  Owing to the market availability of large number of liquid biopsy technologies, the liquid biopsy segment currently accounts for a dominating share in the global minimally invasive biopsy technologies market . However, the market growth in the segment can be attributed to the increasing demand for liquid biopsy and the strong product pipeline. For instance, CNI Second Opinion by Chronix Biomedical is presently under development and is expected to get launched during the forecast period 2019-2030. Owing to a widespread market presence of leading players and the huge prevalence of cancer, North America presently holds a major share in the global minimally invasive biopsy technologies market. According to the World Cancer Research Fund (WCRF), with an estimated 2 million cases in 2018, lung cancer is the most commonly occurring cancer in men and third-most commonly occurring cancer in women. Due to the widespread presence of cancer, the manufacturers including Biocept, Inc., Chron...
Post a Comment
Read more

Global Surgical Robotics Market: Analysis and Forecast, 2018-2025

Global Surgical Robotics Market: Focus on Products and Services (Surgical Systems, Instruments & Accessories, and Services & Maintenance), Applications, End Users, and Competitive Landscape: Analysis and Forecast, 2018-2025. Rising incidences of colorectal cancer, neurological disorders, interventional cardiology disorders and gynecological diseases, growing geriatric population, and active participation of the government and the industry players in the technological advancement in the field of computer assisted robotic surgeries have boosted the overall growth of this market. Another factor which significantly contributes to the revenue generation of a company is the recurring sale of equipment and accessories of a surgical system. The surgical robotics vendors generate revenue through one time sale of the surgical system and generate the recurring  revenue from the sale of equipment and accessory products and maintenance services used in the surgical system. A...
1 comment
Read more